Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Februar 2018 07:00 ET | Quelle: ObsEva SA

ObsEva SA Reports Positive Topline Results from IMPLANT2 Phase 3 Clinical Trial of Nolasiban in IVF

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} The WHO considers infertility a global...
23. Februar 2018 16:00 ET | Quelle: ObsEva SA

ObsEva SA to Hold Investor Call to announce Topline Results of the IMPLANT2 phase 3 Clinical Trial of Nolasiban in IVF/ICSI on Monday February 26, 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
07. Februar 2018 07:00 ET | Quelle: ObsEva SA

ObsEva SA to present at the LEERINK Partners 7th Annual Global Healthcare Conference February 14th 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
01. Februar 2018 07:00 ET | Quelle: ObsEva SA

Dr. Ernest Loumaye, CEO of ObsEva SA returns to work following a personal leave for medical reasons

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
05. Januar 2018 07:00 ET | Quelle: ObsEva SA

ObsEva SA to Participate in JP Morgan Healthcare Conference January 8 - 11, 2018

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
07. Dezember 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA to Participate in BMO Healthcare Conference December 14th 2017

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA...
05. Dezember 2017 07:00 ET | Quelle: ObsEva SA

ObsEva Initiates PROLONG, the Phase 2a Clinical Trial of OBE022 in Preterm Labor

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} OBE022 is a first-in-class, oral and...
14. November 2017 07:00 ET | Quelle: ObsEva SA

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} - All Three Development Compounds...
07. November 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA Announces the Completion of Patient Recruitment in the EDELWEISS Phase 2b Clinical Trial of OBE2109 for the Treatment of Endometriosis

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...
31. Oktober 2017 07:00 ET | Quelle: ObsEva SA

ObsEva SA to Hold Third Quarter 2017 Financial Results and Business Update Call on November 14, 2017 and Present at Credit Suisse and Jefferies Investor Conferences in November

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Geneva, Switzerland and Boston, MA -...

Vorherige Seite

Nächste Seite